New FDA Guidance Aims to Boost Access to Opioid-Reversal Drug

Under new guidance, harm reduction programs distributing naloxone will be exempt from certain federal requirements in an effort to increase access to the opioid antidote.
Medscape Medical News

source https://www.medscape.com/viewarticle/982472?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?